the long term INSM plan becomes apparent . . . for those Longs who care to read!?!
The last two bullets of the Quarterly Report section on clinical development strategy are important. If you are 40 years old, accumulate shares because in 10 years you might be able to have a great "nest egg" for your retirement.
Important statements from WL and INSM:
" · Attempt to develop, acquire, in-license or co-promote promising late stage or commercial products that we believe are complementary to ARIKAYCE and our core competencies; and
· Continue to develop novel formulations of existing therapies, where such reformulation could materially improve the treatment paradigm for the underlying disease or to enable pursuit of a new indication."
WL is looking for drugs that fit into the liposome and is trying to develop INSM's own, proprietary inhalational drug formulations. That is the future of the inhalational drug business. I doubt that he is going to partner or sell INSM in the near future. There is too much going on and too many opportunities.
Hey reh ! sorry I know this is off topic ... but knowing that you are a retired vet I like to know your take on CTIX.
Brilacidin Veterinarian License Worth $50 Million
The post 2b licensing of Brilacidin to veterinarian and more specifically livestock markets could generate enough cash, plus percentage of future sales, that it alone constitutes a non dilutive financing option for Cellceutix through to the end of 2016 (OTCMKTS:CTIX).
Investment folly. Insmed is an r n d co for the next couple of years.If they have another misstep someone will gobble them up for a couple of bucks.Investing in this company for a possible advance in liposomal technology that this company doesn't have a chance in hell to afford for years is crazy,expect a dilution soon
Thx. I think he's already stated that he wants to partner in Asia and, I believe, some other non-US countries. So, I believe that is a given. As for Europe, I seem to recall he was willing to bundle Asia in with Europe - but it is just a memory that may or may not be correct. We will see.
The requirements for a somewhat standard P3 in the setting of having obtained breakthrough suggests that a close look at all the data simply wasn't that compelling. That could well impact what happens in Europe, as well as making the company less viable for a partner looking for near-term revenue. The fact that the CCO simply bailed out for a penny stock company simply confirms that IMO.